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Health, Ingolstädter Landstrasse 1, 85764 Neuherberg, Germany
Received October 7, 2013; Revised May 13, 2014; Accepted May 14, 2014
ABSTRACT
The Fe(II) and 2-oxoglutarate dependent oxygenase
Jmjd6 has been shown to hydroxylate lysine residues
in the essential splice factor U2 auxiliary factor 65
kDa subunit (U2AF65) and to act as a modulator of
alternative splicing. We describe further evidence for
the role of Jmjd6 in the regulation of pre-mRNA pro-
cessing including interactions of Jmjd6 with multi-
ple arginine–serine-rich (RS)-domains of SR- and SR-
related proteins including U2AF65, Luc7-like protein
3 (Luc7L3), SRSF11 and Acinus S′, but not with the
bona fide RS-domain of SRSF1. The identified Jmjd6
target proteins are involved in different mRNA pro-
cessing steps and play roles in exon dependent al-
ternative splicing and exon definition. Moreover, we
show that Jmjd6 modifies splicing of a constitutive
splice reporter, binds RNA derived from the reporter
plasmid and punctually co-localises with nascent
RNA. We propose that Jmjd6 exerts its splice modu-
latory function by interacting with specific SR-related
proteins during splicing in a RNA dependent manner.
INTRODUCTION
Jumonji domain containing protein 6 (Jmjd6) is a mem-
ber of the Fe(II) and 2-oxoglutarate (2OG) dependent oxy-
genase family (1). 2OG oxygenases couple the reaction of
2OG and oxygen with the two-electron oxidation of their
primary substrates (proteins, lipids, nucleic acids or small
molecules) with concomitant production of CO2 and succi-
nate (2). The Jmjd6 protein is highly conserved throughout
the animal kingdom and plays an important role in embry-
onic development. Jmjd6-knock-out experiments in verte-
brates manifest serious developmental defects, e.g. in heart
and brain and embryos died prenatally (3–5). In zebrafish
developmental defects in addition to those involved in car-
diovascular development, include those in somites and the
notochord (6). Interestingly, loss of Jmjd6 function in the
invertebrate Caenorhabditis elegans does not have any com-
parable phenotype (7).
Recently, Jmjd6 has been shown to interact with
U2AF65, to catalyse hydroxylation of lysine residues in
U2AF65 and to regulate alternative splicing (8). The bi-
ological importance of Jmjd6 in pre-mRNA splicing was
demonstrated in mouse endothelial cells where Jmjd6
knockdown changed splicing of the vascular endothe-
lial growth factor (VEGF)-receptor Flt1 pre-mRNA and
thereby promoted expression of a soluble form of the re-
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ceptor, which inhibits angiogenesis by binding to VEGF
(9). More recently, the effect of iron on splicing of the
pre-mRNA for ferrochelatase was demonstrated to work
through regulation of the activity of Jmjd6 (10). However,
Jmjd6 has never been identified in proteomic screens for
components of the spliceosome (11–14) and is therefore
probably not a constitutive part of it. Jmjd6 has also been
reported to modify histones (15–17), the bromodomain
containing protein Brd4 and the tumour suppressor p53
(18,19). Reported targets of the enzymatic activity of Jmjd6
include, on the one hand, lysine residues in histones, p53
and U2AF65 (8,19,20) and, on the other hand, methyl-
arginine residues in histones and ER (16,21). Thus, the de-
tailed nuclear functions of Jmjd6, including the mechanisms
by which it regulates splicing remain to be elucidated.
In the present study, we describe more detailed inves-
tigations on the interaction of Jmjd6 with splice factors.
Jmjd6-pulldown assays revealed Jmjd6 interactions with a
number of SR-like proteins, some of which were confirmed
by co-immunoprecipitation experiments with endogenous
Jmjd6. We show here that Jmjd6 binds the arginine–serine-
rich (RS-) domains of U2AF65, Luc7L3, Acinus S′ and
SRSF11. The interaction of Jmjd6 with the RS-domains of
these target proteins is selective, because the RS-domain of
SRSF1, for instance, is not bound within our limits of de-
tection. The four analysed proteins are involved in differ-
ent splicing and mRNA processing steps. Luc7L3 is the hu-
man homologue of yeast Luc7p, a component of the yeast
U1 snRNP, which is involved in the U1 snRNP interaction
with the nuclear cap binding complex (CBC) (22,23). Ac-
inus is involved in splicing as part of the ASAP-complex,
which contains SAP 18 (Sin 3 associated protein of 18 kDa)
and RNPS1 and blocks the splicing activating function of
RNPS1 (24). Acinus interacts with the core exon junction
complex (EJC) (25). SRSF11 interacts with RNPS1, how-
ever, its function is not well characterised yet. In this study,
we found that Jmjd6 formed a trimeric complex with the
U2AF65/U2AF35 heterodimer. In accordance with these
protein interactions of Jmjd6, we found that jmjd6 knock-
down stimulates splicing of a reporter gene and Jmjd6 over-
expression inhibits it. In high resolution fluorescence mi-
croscopy Jmjd6 protein co-localises with nascent RNA in
HeLa cells. Overall our results support the proposal that
a major function of Jmjd6 is in splicing modulation and
that this is achieved principally via its interaction with RS-
domains of SR-like proteins.
MATERIALS AND METHODS
Cell culture, transfection and immunostaining
HeLa cells and human embryonic kidney (HEK) 293T
cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum, peni-
cillin (100 U ml−1) and streptomycin (100 g ml−1) at 37◦C,
5% CO2. For microscopy HeLa cells were grown to 50–70%
confluence on 18 × 18 glass coverslips and transfected with
expression constructs using Lipofectamine 2000 (Invitro-
gen) according to the manufacturer’s instructions. 24 hours
post-transfection, cells were fixed with 4% paraformalde-
hyde (15 min at room temperature) and permeabilised
with 1% Triton-X-100 in phosphate buffered saline (PBS).
JMJD6 (ab10526, Abcam), anti-BrdU (B8434, Sigma),
anti-HA (H6908, Sigma) and anti-U2AF65 (ab37483, Ab-
cam) were used as primary antibodies, Cy3-coupled anti-
mouse (Jackson Immuno Research), Alexa647 anti-mouse
(Invitrogen) and Alexa488 anti-rabbit (Invitrogen) were
used as secondary antibodies.
Native gel analysis
The native gel analysis has been described recently (26).
Briefly, lysates of HEK-293T cells were loaded on a
non-denaturing native gel (7% acrylamide/bis-acrylamide
(29:1), 80 mM Tris/HCl pH 7.3), blotted and subsequently
stained with the appropriate antibodies. An Odyssey im-
ager (LI-COR) has been used for antibody detection. Sec-
ondary antibodies were goat anti-mouse IRDye800 (926-
32210) and goat anti-rabbit IRDye680 (926-32221). For
RNase treatment RNase A has been added to the lysisbuffer
(final concentration: 1 mg/ml) and incubated for 30 min.
3D-structured illumination microscopy
HeLa cells were grown to 60–70% confluency on 18 ×
18 coverslips. The cells were treated with 20 mM 5-
fluorouridine (5-FU) solved in DMEM for 3 min and then
fixed 10 min with 2% formaldehyde. All washing steps after
fixation were performed with 0.02% Tween in PBS (PBST).
Cells were quenched in saturated glycin-solution and per-
meabilised with 0.5% Triton-X100 in PBS. Blocking was
performed in 2% Bovine serum albumin (BSA) and 0,5%
fish skin gelatin (FSG) in PBST. Primary antibodies used
were: rabbit polyclonal anti JMJD6 (ab10526, Abcam),
mouse monoclonal anti-BrdU (B8434, Sigma) and rab-
bit polyclonal anti-U2AF65 (ab37483, Abcam) Secondary
antibodies (Jackson ImmunoResearch, Molecular Probes)
were coupled to Alexa405 for blue fluorescence, Alexa488
for green fluorescence and Alexa594 for red fluorescence.
Cells were post-fixed with 4% formaldehyde in PBS after in-
cubation with secondary antibodies. After additional wash-
ing steps cells were counterstained with 200 ng/ml DAPI in
PBST for 10 min. Cells were mounted on microscopy slides
with Vectashield mounting medium (Vector Laboratories)
and imaged using the DeltaVision OMX (Applied Preci-
sion).
Co-immunoprecipitation experiments
HeLa cells were transiently transfected with C-terminal
HA-tagged full-length Jmjd6 and green fluorescent pro-
tein (GFP)-tagged variants of either U2AF65, Acinus S′,
SRSF11, Luc7L3 or SRSF1. The GFP-nanotrap (Chro-
moTek GmbH, Germany) has been used for immunopre-
cipitation as described previously (8). For RNase treatment
RNase A has been added to the lysis buffer (final concen-
tration: 1 mg/ml) and incubated for 30 min. Primary an-
tibodies for western blotting were mouse anti-GFP anti-
body (11814460001, Roche) and rabbit anti-HA antibody
(H6908, Sigma).
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In-gel-trypsin digestion and mass spectrometry of GFP-
pulldown samples
The procedure used for analysis of proteins by mass spec-
trometry has been described previously (26).
Immunoprecipitation of endogenous Jmjd6
For each immunoprecipitation experiment ca. 5 × 107 HeLa
cells were grown in DMEM (Biochrom) supplemented with
10% fetal calf serum, penicillin (100 U ml−1) and strepto-
mycin (100 g ml−1) at 37◦C, 5% CO2. Cells were harvested,
lysed for 30 min on ice in lysis buffer (150 mM NaCl, 10
mM Tris–HCl pH 7.5, 0.5% NP-40) and then sonicated for
20 s. After centrifugation, the supernatant was incubated at
4◦C for 2 h with 5 g of anti-Jmjd6 antibody (ab10526, Ab-
cam) and for control with non-specific rabbit IgG (Merck
Millipore). The lysate–antibody complexes were then added
to 50 l of Protein G Sepharose beads (4 fast flow, GE
Healthcare) and incubated for 2 h at 4◦C. Following the
immunoprecipitation, beads were washed four times with
wash buffer 1 (150 mM NaCl, 20mM Tris–HCl pH 7.5) and
four times with wash buffer 2 (300 mM NaCl, 20 mM Tris–
HCl pH 7.5) and then resuspended in Laemmli buffer.
Label-free LC–MS/MS analysis of immunoprecipitation of
endogenous Jmjd6
Each 10 g of IP samples and controls were digested with a
modified filter aided sample preparation (FASP) procedure
(27). Briefly, the proteins were reduced and alkylated using
dithiothreitol (DTT) and iodoacetamide (IAA) and then
centrifuged through a 30 kDa cut-off filter device (PALL,
Port Washington, USA), washed thrice with UA buffer (8
M urea in 0.1 M Tris/HCl pH 8.5) and twice with 50 mM
ammonium bicarbonate. The proteins were digested on the
filter for 2 h at room temperature using 1 g Lys-C (Wako
Chemicals, Neuss, Germany) and for 16 h at 37◦C using 2
g trypsin (Promega, Mannheim, Germany). The peptides
were collected by centrifugation (10 min at 14 000 g), and
the samples were acidified with 0.5% trifluoroacetic acid
(TFA) and stored at −20◦C. Before loading, the samples
were centrifuged for 5 min at 4◦C. LC–MS/MS analysis was
performed as described previously (28). The samples were
automatically injected and loaded onto the trap column at
a flow rate of 30 l/min in 3% buffer B (73% ACN/ 3%
DMSO/ 0.1% formic acid (FA) in HPLC-grade water) and
97% buffer A (2% ACN/ 3% DMSO/0.1% FA in HPLC-
grade water) (29). After 5 min, the peptides were eluted from
the trap column and separated on the analytical column by
a 140-min gradient from 3 to 35% of buffer B at 300 nl/min
flow rate followed by a short gradient from 35 to 95% buffer
B in 5 min. Between each sample, the gradient was set back
to 3% buffer B and left to equilibrate for 20 min. From the
MS prescan, the 10 most abundant peptide ions were se-
lected for fragmentation in the linear ion trap if they ex-
ceeded an intensity of at least 200 counts and if they were
at least doubly charged. During fragment analysis a high-
resolution (60 000 full-width half maximum) MS spectrum
was acquired in the Orbitrap with a mass range from 200 to
1500 Da.
The acquired spectra were loaded to the Progenesis LC–
MS software (version 2.5, nonlinear) for label free quantifi-
cation and analyzed as described previously (28,30). Briefly,
profile data of the MS scans were transformed to peak
lists with respective peak m/z values, intensities, abundances
(areas under the peaks) and m/z width. MS/MS spectra
were treated similarly. After reference selection, the reten-
tion times of the other samples were aligned by automatic
alignment to an overlay of all features of at least 97%. Fea-
tures with only one charge or more than seven charges were
excluded from further analyses. All MS/MS spectra were
exported as Mascot generic file and used for peptide iden-
tification with Mascot (version 2.4) in the Ensembl Hu-
man protein database (release 7 240 047 703 residues, 105
287 sequences). Search parameters used were: 10 ppm pep-
tide mass tolerance and 0.6 Da fragment mass tolerance,
one missed cleavage allowed, carbamidomethylation was set
as fixed modification, methionine oxidation and asparagine
or glutamine deamidation were allowed as variable modi-
fications. A Mascot-integrated decoy database search cal-
culated an average false discovery of <1% when searches
were performed with a mascot percolator score cut-off of 15
and an appropriate significance threshold P. Peptide assign-
ments were re-imported into the Progenesis LC–MS soft-
ware and the abundances of all peptides allocated to each
protein were summed up. The resulting normalized abun-
dances were then used for calculation of enrichment factors
of proteins.
Double-reporter splicing assay
The plasmid pTN24, carrying the -galactosidase (-gal)
and luciferase (luc) gene has been described elsewhere (31).
HeLa cells have been transiently transfected with pTN24
and co-transfected with either empty pcDNA3 plasmid or
full-length Jmjd6 in pcDNA3. -gal and luc activity was
detected in a luminometer (Lumat 9501, Berthold) 24 h
post-transfection. Therefore, cells were lysed with passive
lysis buffer of the dual-luciferase reporter assay system
(Promega, Wisconsin, USA) for 15 min. Lysates were cen-
trifuged at 14 000 g for 1 min. Luc activity was measured
in 10 l of the supernatant by using the dual-luciferase re-
porter assay system (Promega, Wisconsin, USA) and -gal
activity was analysed with the Galacto-Light system (Ap-
plied Biosystems) according to the manufacturer’s instruc-
tions.
Jmjd6 siRNA knock down experiments
Stealth siRNA-132 and siRNA-275 (Invitrogen) have been
used to knock down Jmjd6 in HeLa cells. Jmjd6 siRNA-
132 corresponds to nucleotides 132–156, siRNA-275 cor-
responds to nucleotides 275–299 of the Jmjd6-ORF. As a
control experiment siRNA with no corresponding sequence
in the JMJD6-ORF has been used (si-275-control). Mock-
transfection without siRNA has been used as an additional
control experiment.
HeLa cells were grown to 50–60% confluence in a 12-
well and transfected with 200 nM siRNA (Lipofectamine
2000, Invitrogen) at day 1. At day 2 (24 h post-transfection)
cells were passaged into a 6-well and transfected again
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with 200 nM siRNA. Efficient knock-down of Jmjd6 was
measured at day 5 as monitored with anti-Jmjd6 west-
ern blots. -Galactosidase and luciferase activity for the
double-reporter splicing assay was analysed at day 5 (see
above).
siRNA sequences:
siRNA-132: UAA CGU GGA AAG GGC AGA UGC
UUU A
siRNA-275: GGA AAU AUC GGA ACC AGA AGU
UCA A
siRNA-275-control: GGA UAU GGC CAA GAC GAA
UUA ACA A
The nucleotide sequences of Jmjd6 and Jmjd6AxA in
pcDNA3 plasmid were changed for transient expression in
Jmjd6 knockdown cells (rescue experiment). The nucleotide
changes are not altering the Jmjd6 amino acid sequence.
Nucleotide sequence Jmjd6 wildtype: 132-T AAC GTG
GAA AGG GCA GAT GCT TTA-156
Nucleotide sequence Jmjd6 rescue: 132-C AAT GTA
GAG AGA GCA GAT GCT TTA-156
Reverse transcription/polymerase chain reaction (PCR) of
reporter-gene mRNA
24 hours post-transfection mRNA was isolated from HeLa
cells by using the Quickprep mRNA Purification Kit (GE
Healthcare) and 100 ng of isolated mRNA were used
for cDNA synthesis with the First-Strand cDNA Synthe-
sis Kit (GE Healthcare) according to the manufacturer’s
instructions. PCR was carried out with primers GalFor
and LucRev, which compass the intron region between -
galactosidase and luciferase in the reporter gene mRNA.
The PCR products differ in size by 200 nucleotides due to
occurrence of splicing (unspliced, spliced).
Primer-sequences:
GalFor: AAC ATC AGC CGC TAC AGT CAA
LucRev: ACG TGA TGT TCT CCT CGA TAT
RNA-immunoprecipitation experiments
HEK 293T cells were transiently transfected with
pTN24 (31) and pHA-Jmjd6 plasmids. The RNA-
immunoprecipitation (RIP) was done using the EZ-
Magna-RIP-Kit (Merck Millipore) according to manu-
facturer’s instructions with either an anti-HA antibody
or the corresponding rat-isotype control (ratIgG1, eBio-
science, 16-4301-81 clone eBRG1). Contaminating DNA
was digested prior to first strand cDNA-synthesis (GE
Healthcare) using DNase I (RNase free, Roche). GalFor
and LucRev primers (see above) were used for PCR
amplification.
RESULTS
Jmjd6 co-precipitates with several proteins involved in mRNA
processing
In a previous study, we identified the interaction of Jmjd6
with U2AF65 by tandem affinity purification (TAP-tag)
coupled to mass spectrometry (LC–MS/MS) (8). In this
study, we observed that additional splice related proteins in-
teract with Jmjd6. We now carried out further interaction
screens using GFP-pulldown experiments in HEK 293T
cells (GFP-trap, (32)). We compared these results with the
potential Jmjd6-binding proteins identified in our initial
TAP-tag screen and in a recent pulldown-experiment car-
ried out with HA-tagged Jmjd6 (33). We found 35 pro-
teins appearing in at least three of these four indepen-
dent pulldown experiments (Table 1). Most of them (22/35)
were connected with pre-mRNA processing. Sixteen of
the 22 splicing-associated proteins exhibited an arginine–
serine-rich (RS) domain after Uniprot search and man-
ual inspection (Table 1). Nine of these potential Jmjd6-
target proteins had previously been shown to be present
in the pre-spliceosomal A-complex (summarised in (34)).
Except for SRSF11 none of the potential Jmjd6 targets
belonged to the classical SR-protein family (35). We then
confirmed some of these putative Jmjd6 target proteins by
co-immunoprecipitation (co-IP) with endogenous Jmjd6 in
HeLa cell lysates. Three independent co-IP experiments
were carried out with anti-Jmjd6 antibody and the iden-
tity of co-precipitated proteins was analysed by label-free
LC–MS/MS. Seven of the proteins listed in Table 1 were
identified in all three experiments, including Luc7-like 2 and
SRSF11 (Table 1 and Supplementary Figure S1).
We have previously reported that peptides derived from
RS-domains of U2AF65 and Luc7-like 2 were substrates
for lysyl hydroxylation by Jmjd6. Moreover, we also found
that lysyl residues outside the RS-domain of U2AF65
were hydroxylated by Jmjd6 in vivo and in vitro (8,36).
We thus wanted to establish the interaction site(s) for
Jmjd6 on other RS-domain containing proteins. We se-
lected U2AF65, Luc7L3, Acinus S′ and SRSF11 for fur-
ther analysis because they are involved in different RNA-
processing steps (see ‘Introduction’ section). Figures 1 and
2 show schematics of the domain structures of these four
SR-like proteins.
Jmjd6 interacts with U2AF65, Luc7-like 3, SFSR11 and Ac-
inus S′ via their RS domains
GFP-tagged U2AF65, Luc7L3, SRSF11 and Acinus S′
both in full-length and truncated versions were co-
expressed with HA-tagged Jmjd6 in HEK293T cells (for
schematic representation see Figures 1A and 2A). Af-
ter cell-lysis, proteins were immunoprecipitated using the
GFP-nanotrap method (32), separated by SDS-PAGE, im-
munoblotted and analysed with antibodies against GFP- or
the HA-tag (Figures 1B–I and 2B–I). U2AF65-GFP was
found to co-precipitate with Jmjd6-HA in such an exper-
iment (Figure 1B and C); in contrast truncated U2AF65
lacking the RS domain did not bind to Jmjd6 (Figure
1D). However, the RS domain alone (aa21–70) coupled
to GFP was sufficient for interaction with Jmjd6 (Fig-
ure 1E). Moreover, when we deleted parts of the RS do-
main of U2AF65 it still bound to Jmjd6 (Figure 1F). Co-
immunoprecipitation experiments using Luc7L3-GFP, Ac-
inus S′-GFP and SRSF11-GFP as well as several truncated
versions of both proteins showed that they also did not in-
teract with Jmjd6 in the absence of their RS domains and
that an RS domain alone was sufficient for Jmjd6 binding
(Figures 1G–I and 2B–I).
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Figure 1. U2AF65 and Luc7L3 bind Jmjd6 via their RS domains. The U2AF65 protein exhibits two bona fide RNA binding domains (RRM) and
a modified RRM, the so-called U2AF-homology motif (UHM), and an arginine–serine-rich (RS) domain (aa27–63). Various U2AF65 deletions and
Luc7L3 variants were generated (A) and tested for Jmjd6 binding in co-immunoprecipitation assays (B–F). Full-length U2AF65 coupled to GFP and
HA-tagged Jmjd6 were over-expressed in HEK 293T cells, lysed and immunoprecipitated with the GFP-nanotrap (32). Co-precipitation of HA-tagged
Jmjd6 was tested in immunoblots with anti-HA antibody. Whereas the U2AF65-GFP co-precipitated Jmjd6-HA (C), the GFP-only control did not co-
precipitate Jmjd6-HA (B). A U2AF65 lacking the RS-domain (U2AF65 71–465 GFP) did not interact with Jmjd6-HA (D). The RS-domain of U2AF65
(U2AF65 21–70 GFP) fused to GFP is sufficient to co-precipitate Jmjd6-HA (E). A truncated RS-domain (U2AF65 51–130 GFP) also interacted with
Jmjd6-HA (F). A Luc7L3 variant lacking the RS-domain (Luc7L3 1–291 GFP) did not interact with Jmjd6-HA (H). But full-length Luc7L3-GFP (G) and
the RS-domain of Luc7L3 fused to GFP (Luc7L3 292–432 GFP) are sufficient to co-precipitate Jmjd6-HA (I). In = input, F = flow-through, B = beads.
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Figure 2. Acinus S′ and SRSF11, but not SRSF1 bind Jmjd6 via their RS domains. The domain structure of full-length Acinus S′, SRSF11, SRSF1
and deletions as investigated are shown schematically (A). GFP-tagged proteins were over-expressed with HA-tagged Jmjd6 in HEK 293T cells, lysed
and immunoprecipitated with the GFP-trap (32). The SRSF11 protein fused to GFP co-precipitated Jmjd6-HA (B). The RS domain of SRSF11 is also
sufficient to interact with Jmjd6-HA (D, E). SRSF11 variants lacking the RS domain did not interact with Jmjd6-HA (C, F). Acinus S′-GFP co-precipitated
Jmjd6-HA (G), but not the truncated Acinus S′ version, lacking the RS domains (Acinus S′ 47–447 GFP) (H). The first RS domain (Acinus S′ 447–510
GFP) is sufficient to pull down Jmjd6-HA (I). The ‘classical’ SR–protein SRSF1 (37) exhibits an RS domain, but did not interact with Jmjd6-HA in our
experiments (J). Fusing the RS-domain of SRSF1 to GFP also did not pull down Jmjd6-HA (K). In = input, F = flow-through, B = beads.
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Q9Y383 Putative RNA-binding protein Luc7-like 2 + + + + + +
Q9NQ29 Putative RNA-binding protein Luc7-like 1 + + + + + +
O95232 Luc7-like protein 3 + + + + + +
Q16630 Cleavage and polyadenylation specificity factor subunit 6 + + + + − +
Q01081 Splicing factor U2AF 35 kDa subunit + + + + − +
P26368 Splicing factor U2AF 65 kDa subunit + + + + + +
Q05519 Serine/arginine-rich splicing factor (SRSF) 11 + + + + + +
Q14498 RNA-binding protein 39 + + + + + +
Q7L4I2 Arginine/serine-rich coiled-coil protein 2 + + − + − +
Q7L014 Probable ATP-dependent RNA helicase DDX46 + + + + − +
Q8WXA9 Splicing regulatory glutamine/lysine-rich protein 1 + + − + − +
Q9UQ35 Serine/arginine repetitive matrix protein 2 + + − + − +
O75400 Pre-mRNA-processing factor 40 homolog A + + + + − +
Q9UKV3 Apoptotic chromatin condensation inducer in the nucleus (Acinus) + + + − − +
Q8N5F7 NF-kappa-B-activating protein + + + + − +
Q96IZ7 Serine/Arginine-related protein 53 + − + + − +
O43809 Cleavage and polyadenylation specificity factor subunit 5 + + − + − −
Q9UHX1 Poly(U)-binding-splicing factor PUF60 + + + + + −
Q15637 Splicing factor 1 + + − + − −
Q13435 Splicing factor 3B subunit 2 + + − + − −
Q9UJV9 Probable ATP-dependent RNA helicase DDX41 + − + + − −
P05455 Lupus La protein + + − + − −
P11142 Heat shock cognate 71 kDa protein + + − + − −
P38646 Stress-70 protein, mitochondrial + + − + − −
P08107 Heat shock 70 kDa protein 1A/1B + + − + − −
P06748 Nucleophosmin + + − + − −
P50990 T-complex protein 1 subunit theta + + − + − −
P50991 T-complex protein 1 subunit delta + + − + − −
Q99832 T-complex protein 1 subunit eta + + − + − −
P10599 Thioredoxin + + − + − −
Q15084 Protein disulfide-isomerase A6 + + − + − −
P62263 40S ribosomal protein S14 + + − + − −
Q9BU76 Multiple myeloma tumor-associated protein 2 + − + + − −
Q15365 Poly(rC)-binding protein 1 + + − + − −
Q15366 Poly(rC)-binding protein 2 + + − + − −
Summary of putative Jmjd6 binding proteins identified in two independent GFP-pulldown assays (IP 1 + 2) coupled to mass spectrometry (LC–MS/MS)
after transient expression of Jmjd6-GFP in HEK 293T cells and comparison with recently published Jmjd6 pulldown results using TAP-tagged (8) or
HA-tagged Jmjd6 in 293T cells (33). Only such proteins are listed that appeared in at least three of these four independent pulldown experiments. Column
‘endogenous interaction’ indicates Jmjd6–protein interactions that have been confirmed to occur on endogenous level, including this work and (8). Proteins
connected to pre-mRNA processing are indicated in bold. Presence of RS-domains as defined by www.uniprot.com and as found by manual inspection is
indicated in column ‘RS-domain’.
The specific interaction of Jmjd6 with RS-domains of
different proteins poses the question why the classical SR–
proteins (37) had not been enriched in any of the Jmjd6-
interaction screens. We therefore analysed SRSF1 (Fig-
ure 2A). SRSF1-GFP pulldown in HEK293 cells did not
co-precipitate HA-tagged Jmjd6 within limits of detection
(Figure 2J). This was also true for the isolated RS-domain
of SRSF1 fused to GFP (Figure 2K). Thus, the observed
Jmjd6-RS-domain interactions exhibit specificity.
The interaction of Jmjd6 with U2AF65, Acinus S′,
Luc7L3 and SRSF11 was validated using native gel elec-
trophoresis assays. Cells were co-transfected with plasmids
encoding GFP-tagged versions of these proteins and HA-
tagged Jmjd6. Lysates were then analysed using native Tris–
borate–EDTA (TBE) gels. U2AF65-GFP did not run into
the gel in significant amounts under these conditions. How-
ever, when Jmjd6 was co-expressed, both proteins migrated
into the gel and were observed in two bands migrating
slightly slower than Jmjd6 alone (Figure 3A). Acinus S′-
GFP also did not migrate into the gel. When Jmjd6 was
over-expressed, both proteins co-migrated as one strong
band, migrating more slowly than Jmjd6 alone (Figure 3B).
A similar result was obtained for SRSF11-GFP, which only
marginally migrated into the gel alone. However, in the pres-
ence of Jmjd6, SRSF11-GFP was observed to migrate as
a single strong band (Figure 3C). In contrast to Acinus S′
and SRSF11, Luc7L3-GFP always migrated into the gel by
itself. Nevertheless, with Jmjd6 a faster migrating second
Luc7L3 band co-localising with Jmjd6 (Figure 3D) was ob-
served. These data confirmed that Jmjd6 interacts with the
selected SR-like proteins.
We then treated lysates with RNase before separating the
proteins by native gel electrophoresis. In this case, migration
of Jmjd6 into the gel was compromised and consequently,
U2AF65 also did not migrate into the gel (Figure 4A). In
samples over-expressing Luc7L3, the protein ran into the
gel just as it did in the absence of over-expressed Jmjd6 (Fig-
ure 4B). However, when Jmjd6 was over-expressed together
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Figure 3. U2AF65, Acinus S′, SRSF11 and Luc7L3 interact with Jmjd6 oligomers. Jmjd6 assembles as oligomers in cells and these oligomers have been
shown to run into native gels (26). We have tested whether Jmjd6 oligomers interact with substrate proteins by comparing the performance of proteins
in native gels. Lysates of 293T cells expressing either HA-tagged Jmjd6 (lanes I) or substrate-GFP (U2AF65, Acinus S′, SRSF11, Luc7L3) (lanes II) or
co-expressing both proteins (lanes III) were separated on native gels. Subsequently western blots were co-analysed with anti-HA antibody (Jmjd6) and
anti-GFP antibody (green arrows) (U2AF65, Acinus S′, SRSF11, Luc7L3). Yellow bands in merged images indicate co-localisation of proteins in these
bands (yellow arrows, red and green arrows indicate the same bands in single colour images). U2AF65-GFP did not run into the native gel significantly (A,
II), but co-expression with Jmjd6-HA resulted in two prominent bands of U2AF65-GFP (green arrows in A, III), which co-localise with Jmjd6-HA bands
(red arrows in A, III). Acinus S′-GFP did also not run into the native gel (B, II). In the presence of Jmjd6-HA it ran into the gel and co-migrated with
Jmjd6 (green and red arrow in B, III). SRSF11-GFP did not run into the native gel significantly (C, II), but in the presence of Jmjd6-HA SRSF11-GFP
co-migrated with Jmjd6 (green and red arrow in C, III). In contrast to U2AF65, Acinus S′ and SRSF11, Luc7L3 always ran into the gel in the absence of
Jmjd6-HA (blue asterisk in D, II). Co-expression of Jmjd6-HA resulted in a prominent band representing a Luc7L3–Jmjd6 complex (green and red arrow
in D, III).
with Luc7L3, a Luc7L3–Jmjd6 complex was not observed
after RNase treatment. In these experiments Jmjd6 failed
to migrate into the gel after RNase treatment suggesting
that Jmjd6 only moves towards the positively charged pole
when it is bound to RNA. This is consistent with the basic
character of Jmjd6 protein, which has an isoelectric point of
8.8. Luc7L3, which entered the gel after RNase treatment
was not able to recruit Jmjd6 under these conditions (Fig-
ure 4B). In the presence of Acinus S′ and SRSF11 we ob-
served that Jmjd6 had still migrated into the gel and formed
a complex with the respective SR–protein, however, migra-
tion of the complexes was retarded. This may indicate that
the oligomerisation state of Jmjd6 had changed (26). It is
also possible that RNA was protected partially in Acinus–
Jmjd6 and in SRSF11–Jmjd6 complexes (Figure 4C and D).
Previous work had revealed that the interaction of Jmjd6
with U2AF65 is abolished by treatment of the samples
with RNase before precipitation (8). When samples with
Luc7L3-GFP and Acinus S′-GFP were treated with 1
mg/ml RNase before GFP-pulldown, Jmjd6 was not co-
precipitated (Figure 4E–G). In contrast, the interaction of
Jmjd6 with SRSF11 was almost not affected by RNase (Fig-
ure 4H). These observations are consistent with our results
from native gel electrophoresis. They imply that RNA is in-
volved in targeting Jmjd6 to selected partner proteins.
Jmjd6 co-localises with nascent RNA
It had been reported previously that Jmjd6 can bind
to RNA in vitro (38). We therefore investigated whether
Jmjd6 co-localises with nascent RNA in cells. HeLa-cells
were treated with FU for 3 min to label nascent RNA
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Figure 4. Interaction of Jmjd6 and SR–proteins is RNA dependent. The bands representing Jmjd6–SR–protein complexes in native gels disappear upon
RNase A treatment. Both, Jmjd6 and U2AF65 were not found migrating into the gel after RNase treatment (A). Luc7L3 entered the gel after RNase A
treatment, but was not able to recruit Jmjd6 (B). In case of Acinus S′ (C) and SRSF11 (D) the position of the Jmjd6–SR–protein complex was shifted
upon RNase treatment. Complexes are indicated by arrows (A–D, red and green arrows indicate single colour bands that are co-localised as seen with
yellow arrows in merged images). + = RNase A treatment; − = no RNase A treatment. RNase A treatment of 293T cell lysates from cells transfected with
plasmids encoding GFP-tagged and HA-tagged proteins as indicated prior to anti-GFP pulldown, SDS-PAGE and western blot resulted in a breakdown
of interaction of Jmjd6 with the SR–proteins U2AF65 (E), Luc7L3 (F) and Acinus S′ (G) but not with SRSF11 (H). In = input, F = flow-through, B =
beads. Upper panels show precipitation of GFP-tagged proteins, lower panels show co-precipitation of HA-tagged proteins.
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and FU-labelled RNA was subsequently detected with an
anti-BrdU antibody. Cells were then co-stained with anti-
Jmjd6 antibody. Laser confocal microscopy showed co-
localisation of endogenous and overexpressed HA-tagged
Jmjd6 with FU in several single dots (Figure 5A and B).
High-resolution microscopy and 3D SIM (structured il-
lumination microscopy) reconstruction (39) revealed co-
localisation of endogenous Jmjd6 with nascent RNAs in
very distinct dots in the nucleoplasm (Figure 5C). U2AF65
has been shown to be associated with mRNAs in sev-
eral previous studies (40,41). In a control experiment en-
dogenous and overexpressed HA-tagged U2AF65 also co-
localises with nascent RNA in spots that are similar in ap-
pearance and number to the Jmjd6-co-localisation signals
(Figure 6A and B). This was also shown in high-resolution
microscopy and 3D SIM reconstruction (Figure 6C and D).
When we overexpressed U2AF65-GFP it was observed
to partially localise to nuclear speckles. However, signals
outside the speckles were largely found co-localised with
nascent RNA. Endogenous Jmjd6 in such cells appeared to
co-localise with nascent RNA very strongly too and also
co-localised with U2AF65 (Figure 6E). These data indicate
that Jmjd6 might associate with U2AF65-containing pro-
tein complexes on nascent RNA.
We therefore asked whether Jmjd6 was found in a com-
plex with the U2AF65/U2AF35-dimer, which associates
with the polypyrimidine tract and the AG-dinucleotide of
the 3′ splice site during formation of the pre-initiation com-
plex (42,43).
Trimeric complex U2AF65/U2AF35/Jmjd6
Figure 7A shows that U2AF65-GFP immunoprecipitates
with both U2AF35 and Jmjd6, when all three proteins were
over-expressed in HEK293T cells. Similarly, U2AF35-GFP
precipitated both, U2AF65 and Jmjd6 (Figure 7B and C).
When the samples were treated with RNase, U2AF65 was
still precipitated with GFP-U2AF35, indicating that this in-
teraction was not sensitive to RNase, which is in accordance
with previously published data (44). However, Jmjd6 was
not present in the complex after RNase treatment (Figure
7D). We then analysed the Jmjd6–U2AF65–U2AF35 com-
plex on native TBE gels. When U2AF65 and U2AF35 were
over-expressed they did not run into native TBE gels. When
we additionally overexpressed Jmjd6 all three proteins ap-
peared in one band, an additional band containing only
Jmjd6 and U2AF65 was also seen (Figure 7E). All Jmjd6,
U2AF65 and U2AF35 interaction was abolished after treat-
ment of the samples with RNase (Figure 7F).
In order to analyse whether formation of the trimeric
U2AF65/35/Jmjd6 complex is dependent on an intact
U2AF65/U2AF35 interaction we mutated the U2AF65
interaction surface for U2AF35 by replacing the Trp-
finger motif of U2AF65 (45) with alanine/glycine residues
(U2AF65-mutTrp: W92A, P96G, P104G). In contrast to
the interaction of U2AF35 and U2AF65-mutTrp, inter-
action of Jmjd6 with U2AF65-mutTrp was still observed
in GFP-pulldown assays (Figure 8A and B). However, a
trimeric complex was clearly not observed in native gel
electrophoresis (Figure 8C). Thus, formation of a trimeric
Jmjd6/U2AF65/U2AF35 complex is dependent on a suffi-
ciently intact U2AF65/U2AF35 interaction.
Jmjd6 inhibits splicing of a dual reporter gene
Given the interaction of Jmjd6 with the U2AF65/U2AF35
dimer and its co-localisation with nascent RNA we next
analysed whether constitutive splicing was sensitive to the
protein level of Jmjd6 in a cell using a constitutive dual
reporter assay (31). The reporter plasmids encode two
enzymes, -galactosidase and luciferase. Their coding se-
quences are separated by an intron exhibiting three stop-
codons in frame with the -galactosidase coding sequence
(Figure 9A). If this intron is spliced, both enzymes are ex-
pressed and their activities can be measured. In the absence
of splicing, however, only -galactosidase is expressed. The
reporter mRNA was spliced much less efficiently, when
Jmjd6 was over-expressed in HeLa cells. This was seen by
the lower ratio of luciferase to -galactosidase activity (Fig-
ure 9B and D). Expression of a Jmjd6 double mutation
with H187 and D189 changed to alanine, which is catalyti-
cally inactive in vitro (8), had the same effect. On the other
hand, Jmjd6 knockdown using siRNAs showed the oppo-
site effect (Figure 9E and F). Expression of either Jmjd6
or the catalytically inactive Jmjd6 variant in Jmjd6 knock-
down cells in a rescue experiment again reduced splice effi-
ciency, indicating that Jmjd6 mediated splice inhibition was
independent of its catalytic activity (Supplementary Figure
S2). We confirmed that we were looking at splice inhibition
by Jmjd6 by RT-PCR for the spliced and unspliced tran-
scripts. The PCR products we obtained reflected the ratio
of spliced to not spliced RNA that was indicated by com-
parison of the enzyme activities (Figure 9D). We also con-
trolled the expression levels of Jmjd6 after over-expression
and knockdown by SDS-PAGE and western blotting (Fig-
ure 9C and F). This indicated that Jmjd6 mediated splice
inhibition of the reporter gene. We therefore investigated
whether HA-tagged Jmjd6 bound to the plasmid derived
mRNA. HA-tagged Jmjd6 showed the same effect on splic-
ing as untagged Jmjd6 (Figure 9B and G). We found that
the anti-HA antibody, but not the isotype specific con-
trol antibody, immunoprecipitated HA-tagged Jmjd6 (Fig-
ure 9H) and co-immunoprecipitated both, spliced and un-
spliced plasmid derived RNA (Figure 9I). This demon-
strates that HA-Jmjd6 interacts with mRNA, either directly
or indirectly.
DISCUSSION
In this study, we have sought to understand the underly-
ing molecular interactions involved in the splice modula-
tory function of Jmjd6. We found, that Jmjd6 interacts with
multiple splice proteins, many of which have RS-domains.
However, a closer analysis revealed that (with one excep-
tion for SRSF11) these do not include the so-called ‘classi-
cal’ SR–proteins, which have recently been defined as having
one or two RNA binding motifs (RRMs) and a C-terminal
RS-domain with a length of at least 50 amino acids, 40% of
which should be RS or SR repeats (37). Instead, we find
a subset of SR-like proteins with lesser numbers of RS-
dipeptides, partially C-terminally located and also varying
RNA-binding domains interacting with Jmjd6.
Nucleic Acids Research, 2014, Vol. 42, No. 12 7843
Figure 5. Jmjd6 co-localises with nascent RNA. HeLa cells were treated with 5-fluorouridine (5-FU) for 3 min and subsequently stained with anti-
BrdU and anti-Jmjd6 antibody. Yellow dots indicate endogenous Jmjd6 (A) or overexpressed HA-tagged Jmjd6 (B) co-localising with nascent RNA in
confocal microscopy. High-resolution microscopy and 3D SIM reconstruction (39) also revealed co-localisation of endogenous Jmjd6 with nascent RNA
in individual nucleoplasmic spots. DNA is counterstained with DAPI. Central mid-sections of HeLa cell nuclei. Scale bars: 5 m.
We carefully studied the interaction of Jmjd6 with
Luc7L3, Acinus S′, SRSF11 and U2AF65; the results reveal
that the presence of the RS-domains is essential for Jmjd6
interactions. In contrast, the classical SR–protein SRSF1
did not detectably interact with Jmjd6 in cells as was also
observed for its isolated RS-domain. The RS-domain of
SRSF1 comprises 50 residues with 14 repeats of an RS or
SR dipeptide sequence. The RS-dipeptide content of the
RS-domains of Acinus S′, Luc7L3 and U2AF65 is consid-
erably lower than that of SRSF1, ranging from 20 to 32%
(Supplementary Figure S3). An incomplete RS-domain of
U2AF65, which also bound to Jmjd6 only contained 10 RS-
repeats over a length of 50 amino acids. Thus, although clus-
ters of RS-dipeptides comprise a common feature of Jmjd6
interaction domains, these alone are not sufficient. Overall
these results imply that there is selectivity in terms of the
RS-domains targeted by Jmjd6 though it is important to
note that the selectivity may be context dependent.
Previously reported data have shown that Jmjd6 binds to
RNA in vitro (38). In our experiments, the interaction of
Jmjd6 with SR-like proteins was sensitive to RNase treat-
ment to varying degrees. After treatment with RNase un-
complexed Jmjd6 no longer migrated into native TBE gels,
indicating that the Jmjd6 oligomers we have identified on
these gels before (26), are probably bound to RNA.
How can these data shed light on the function of Jmjd6
during splicing? In high-resolution microscopy we observed
that Jmjd6 co-localises with nascent RNA in cells. U2AF65
is associated with pre-mRNA co-transcriptionally (40) and
the co-localisation with nascent RNA that we observe very
likely reflects this. Moreover, we also showed that Jmjd6 en-
gages in a trimeric complex with the U2AF-dimer (U2AF65
and U2AF35). This was not simply caused by its interac-
tion with RS-domains of U2AF65 and U2AF35, because
the complex was dependent on an intact interaction of both
U2AF subunits, which is mediated by contact of the 35 kDa
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Figure 6. U2AF65 co-localises with nascent RNA. HeLa cells were treated with 5-fluorouridine (5-FU) for 3 min and subsequently stained with anti-BrdU
and anti-Jmjd6 antibody. Discrete yellow dots indicate endogenous U2AF65 (A and C) or overexpressed HA-tagged U2AF65 (B and D) co-localising with
nascent RNA in both confocal microscopy (A and B) and high-resolution microscopy and 3D SIM reconstruction (39) (C and D). Confocal cross-section
showing GFP-U2AF65 over-expressing HeLa cells treated with 5-FU and stained with anti-Jmjd6 antibody (E). DNA is counterstained with DAPI.
Central mid-sections of HeLa cell nuclei. Scale bars: 5 m.
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Figure 7. Jmjd6 forms a trimeric complex with U2AF65 and U2AF35 and RNA. GFP-tagged U2AF65, HA-tagged U2AF35 and Jmjd6 (pcDNA3) were
co-expressed in 293T cells. The anti-GFP-pulldown of U2AF65-GFP resulted in co-precipitation of U2AF35 and Jmjd6 (A). Anti-GFP-pulldown of
U2AF35-GFP resulted in co-precipitation of HA-tagged U2AF65 and Jmjd6 (C), a GFP-only control did not co-precipitate either of the two proteins
(B). Treatment with RNase A prior to anti-GFP pulldown did not abolish the interaction of the U2AF dimer, but Jmjd6 disappeared from the complex
(D). In = input, F = flow-through, B = beads. Lysates of 293T cells overexpressing U2AF65-GFP and U2AF35-HA were separated on a native gel and
subsequently western blotted. Western blots were co-stained with indicated antibodies, yellow arrows indicate merged images. U2AF65-GFP and U2AF35-
HA did not run into the native gel (E, 1). The co-expression of untagged Jmjd6 (pcDNA3) resulted in two distinct Jmjd6–U2AF65 complex bands (red
and green arrows in E, left panel). U2AF35 was only present in one of these two bands (red and yellow arrow in E, right panel). Treatment with RNase A
destroyed the Jmjd6–U2AF65–U2AF35 complex, as shown by disappearance of indicated bands in the RNase treated samples (F).
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Figure 8. U2AF65–U2AF35 interaction is essential for Jmjd6 complex formation. Interaction of the U2AF-heterodimer is based on recognition of a
specific tryptophane finger motif in U2AF65 by a modified RRM of U2AF35 (45). Mutation of the U2AF35 binding site in U2AF65 (U2AF65-mutTrp:
W92A, P96G, P104G) inhibited the co-immunoprecipitation of HA-tagged U2AF65-mutTrp by GFP-tagged U2AF35 (A). In contrast, GFP-tagged Jmjd6
is able to pull down both, wildtype and mutTrp U2AF65 (B). Lysates of 293T cells overexpressing Jmjd6 (pcDNA3), U2AF35-GFP and either wildtype
HA-tagged U2AF65 (lane 1) or HA-tagged U2AF65-mutTrp (lane 2) were separated on a native gel (C). As in Figure 7 two bands show co-migration
of Jmjd6 with U2AF65 (red, green and yellow double arrows, left hand panel. (1) The slower migrating band contains U2AF35 (right hand panel, 1).
With U2AF65-mutTrp the U2AF35-containing band is not present (both panels, (2) a trimeric U2AF65–U2AF35–Jmjd6 complex is not observed with
U2AF65-mutTrp.
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Figure 9. Jmjd6 abundance affects constitutive pre-mRNA splicing. The double-reporter splicing assay has been described previously (31). The pTN24
plasmid carries a -galactosidase (-gal) and a luciferase (luc) gene in frame, but separated by an intron. This intron encodes three translational stop codons
(in-frame). The splice-site sequences are based on the genes encoding adenovirus (Ad) and the skeletal muscle isoform (SK) of human tropomyosin. Efficient
splicing removes the translational stop codons and results in a fusion protein of both reporter genes, -gal and luc. Plasmid is shown schematically in (A).
Activities of luc and -gal proteins have been measured after transient transfection of either pTN24 and pcDNA3-Jmjd6 or pTN24 and pcDNA3-Jmjd6-
AxA or pTN24 and empty pcDNA3 plasmid in HeLa cells. Jmjd6 overexpression results in a decrease of splicing of the reporter mRNA, as seen in a
decrease of luc activity (B). The same effect has been observed upon overexpression of a potentially enzymatic inactive Jmjd6 H187A&D189A variant (B).
RT-PCR analysis confirmed the shift to an unspliced mRNA upon overexpression of Jmjd6 (D). Amounts of Jmjd6 protein in cells have been confirmed by
western blot with anti-Jmjd6 antibody (C). siRNA-mediated knock-down of Jmjd6 increases splicing activity (E). Efficient knock-down of Jmjd6 protein
has been detected by western blotting with anti-Jmjd6 antibody (F). Transient expression of HA-tagged Jmjd6 in HEK 293T cells resulted in a similar
decrease of splicing of the reporter gene as observed with untagged Jmjd6 (G). HEK 293T cells transiently transfected with pTN24 and pHA-Jmjd6
were used for RNA-immunoprecipitation with either anti-HA or isotype specific control antibody. Specific immunoprecipitation of HA-tagged Jmjd6 was
confirmed in western blots with anti-Jmjd6 or anti-HA antibody (H). Co-immunoprecipitation of reporter gene mRNA (spliced and unspliced) has been
shown by RT-PCR (I). Error bars represent standard deviation of three independent experiments.
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subunit homology domain on the small subunit with a Trp-
finger motif on the 65 kDa subunit (44).
Considering the overall results, the most likely scenario
is that the role of Jmjd6 in modelling splicing includes its
interaction with pre-mRNA while it interacts with the RS-
domains of SR–proteins, thus modulating the splicing pro-
cess. The sequence of Jmjd6 binding to nascent RNA or
SR–proteins is presently unclear. Jmjd6 may be targeted by
specific interactions with SR-like proteins, thus be recruited
to the nascent RNA. Alternatively, Jmjd6 may recognise
certain RNA sequences targeting it to splice sites, where it
recruits RS-domain containing SR–proteins. Alternatively,
a combination of both may be possible. However, Jmjd6
modulates pre-mRNA splicing and intron removal is af-
fected, as clearly observed with constitutive splice reporter
analyses. Jmjd6 overexpression was observed to decrease
splicing of the reporter when Jmjd6 knockdown increased
it. Moreover, Jmjd6 was co-precipitated with mRNA de-
rived from transcription of the reporter plasmid. These data
are in support of previous studies implying a role for Jmjd6
in pre-mRNA splicing (8–10,46).
The interaction of Jmjd6 with multiple SR–proteins, at
least sometimes in an RNA dependent manner leads to the
proposal that it acts as a facilitator protein for the fine-
tuning of SR–protein functions. This role is likely to be
highly context dependent and regulated by other multiple
factors, including the Jmjd6 oligomerisation state. Jmjd6
forms large oligomers with a ring or a fibrillar structure de-
pending on the presence of a serine-rich (polyS)-domain.
Whilst wildtype Jmjd6 is localised mainly in the nucleo-
plasm, polyS-domain deleted versions of Jmjd6 are found
in nuclear speckles and in the nucleolus (26).
SR–proteins function in many nuclear processes includ-
ing splicing and transcriptional regulation (47). They have
also been implicated in the process of transcriptional paus-
ing of RNA polymerase II, where Jmjd6 has recently been
shown to play a role in regulating promoter-proximal pause
release (18,48).
Jmjd6 is most closely related to the enzyme factor inhibit-
ing hypoxia inducible factor (FIH), which catalyses the hy-
droxylation of an asparagine residue in the C-terminal tran-
scriptional activation domain of hypoxia inducible factor
(HIF) alpha isoform (49,50); a modification that reduces the
transcriptional activity of HIF in a proposed oxygen sens-
ing mechanism, by preventing its interaction with 300 kDa
coactivator protein (p300) (51). In addition to HIF-alpha
FIH also accepts multiple other hydroxylation substrates of
the ankyrin repeat domain containing protein family (52). It
is proposed that the extent of the catalysed ankyrin hydrox-
ylation regulates the amount of FIH available to hydrox-
ylate HIF-alpha (53). Moreover, hydroxylation of ankyrin
repeats has been shown to enhance their stability and this
could be important for the function of this protein–protein
interaction domain (54).
Jmjd6 was shown to hydroxylate specific lysine residues
outside the RS-domain in U2AF65. At the same time it
very efficiently hydroxylates RS-domain derived peptides
(8), which makes it likely that the RS-domains, which bind
to Jmjd6 are also hydroxylated on lysine residues. However,
splice inhibition in our experiments seemed to be indepen-
dent of its enzymatic activity, and therefore Jmjd6-binding
of RS-domains may be sufficient for splice inhibition of the
reporter gene.
In conclusion, we suggest that Jmjd6 interacts with RS-
domains of specific SR-like proteins in a context depen-
dent manner and thus participates in RNA-protein com-
plexes, which form during splicing. In agreement with this
Jmjd6 has an effect on splicing of a reporter gene. The
function of the enzymatic dioxygenase activity of Jmjd6 in
this context is presently not clear. Possible targets for hy-
droxylation include SR-like proteins, RNA and/or methy-
lated RNA. Moreover, Jmjd6 autohydroxylation could be
involved (8,18,54). This problem is more difficult to investi-
gate than for FIH because Jmjd6 engages in multi-protein–
RNA complexes.
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